Skip to content

Dr. Gearóid Tuohy

An investigation of the association between Retinitis pigmentosa (RP) and depressive disorder, including a call for practical training and methods.

Researchers at the Department of Ophthalmology, Ajou University School of Medicine, Suwon, Republic of Korea, have outlined an increasing future burden of depressive disorders, providing… Read More »An investigation of the association between Retinitis pigmentosa (RP) and depressive disorder, including a call for practical training and methods.

A novel induced pluripotent stem cell model shows a mechanistic defect and potential therapy for AMD and related macular dystrophies.

Researchers at the Department of Ophthalmology, and the Center for Visual Science, University of Rochester, New York, have reported a study using induced pluripotent stem… Read More »A novel induced pluripotent stem cell model shows a mechanistic defect and potential therapy for AMD and related macular dystrophies.

An update of clinical trial endpoints provide a dynamic trial environment across a range of inherited retinal degenerations (IRDs).

Clinical researchers at the Department of Ophthalmology, Bascom Palmer Eye Institute, in the University of Miami, Florida, have presented an update on clinical trial endpoints… Read More »An update of clinical trial endpoints provide a dynamic trial environment across a range of inherited retinal degenerations (IRDs).

EyePoint Pharmaceuticals announce interim results from a Phase 2 EYP-1901 treatment (a tyrosine kinase inhibitor with a sustained delivery insert) for DME patients.    

EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), based in Watertown, Massachusetts, have announced positive interim 16-week data for an ongoing Phase 2 “VERONA” clinical trial, evaluating “DURAVYU”… Read More »EyePoint Pharmaceuticals announce interim results from a Phase 2 EYP-1901 treatment (a tyrosine kinase inhibitor with a sustained delivery insert) for DME patients.